GSK1120212 Rollover Study
NCT01376310
Terminated
This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2019
Locations: Novartis Investigative Site, Goodyear, Arizona +18 locations
Conditions: Cancer
Register for Updates
Neoadjuvant Treatment of Breast Cancer
NCT00254592
Completed
Study Aims 1. To measure the clinic response rates in patients with breast cancer more than 2 cm and/or lymph node positive breast cancer treated with 2-4 cycles of biweekly doxorubicin, cyclophosphamide with Granulocyte-macrophage colony-stimulating factor (GM-CSF) (days 4-13) followed by weekly carboplatin/nab-paclitaxel given for 3 weeks, followed by 1 week of rest, for a total of 9-12 doses. (Her-2 positive patients, in addition, will receive Trastuzumab weekly (12-16 doses) and Her-2 negat... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/13/2019
Locations: Chao Family Comprehensive Cancer Center, Orange, California
Conditions: Breast Cancer
Register for Updates
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
NCT02409355
Terminated
This randomized, open-label study was designed to evaluate and compare the safety and efficacy of atezolizumab with gemcitabine + cisplatin or carboplatin in PD-L1 selected participants with chemotherapy-naive, Stage IV squamous NSCLC. The study was closed due to low patient enrollment and the Sponsor's decision to include patients with squamous NSCLC into the GO29431 study, NCT02409342. Therefore the planned objectives of this study are no longer applicable and formal analyses of efficacy or sa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2019
Locations: California Cancer Associates for Research & Excellence, Inc., Encinitas, California +81 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
NCT00002600
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation and peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with carboplatin and cyclophosphamide followed by bone marrow and peripheral stem cell transplantation in treating patients who have advanced ovarian... Read More
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
02/04/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +1 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
NCT00179881
Completed
Treatment on this study combines two drugs: Thalomid™ (thalidomide) and carboplatin. Thalidomide has been available for many years and has been used to treat many different illnesses. Carboplatin is an effective medicine in killing cancer cells. Thalidomide works by blocking angiogenesis (the process of new blood vessel formation). If a tumor does not have blood vessels providing oxygen and nutrients, it will not be able to grow. This research will look at how combining the effects of thalidomid... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
02/01/2019
Locations: Phoenix Children's Hospital, Phoenix, Arizona +5 locations
Conditions: Brain Stem Neoplasms, Primary, Neoplasms, Brain Stem
Register for Updates
Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
NCT00424840
Terminated
A pilot trial of combination of bortezomib, bevacizumab and carboplatin as first line therapy in patients with metastatic Non-Small Cell Lung Cancer (NSCLC). Phase I and II study of this combination in first line setting will be conducted in order to properly estimate the efficacy and safety of this regimen. This will form the basis for future studies comparing this combination to what is now considered standard regimen for first line therapy in patients with NSCLC, carboplatin, paclitaxel and b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2019
Locations: University of Massachusetts Medical School, Worcester, Massachusetts
Conditions: Lung Cancer
Register for Updates
A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC
NCT02364999
Completed
This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2019
Locations: Southern Cancer Center, PC, Daphne, Alabama +262 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens
NCT00681993
Completed
Breast conserving therapy, (BCT), which consists of wide local excision of the tumor followed by 6 weeks of whole breast irradiation, (WBI), is integral to the management of breast cancer. Evidence now suggests that WBI may not be necessary and treatment to the involved area only, partial breast irradiation, (PBI), may suffice. PBI can be achieved by interstitial or intracavitary brachytherapy, intra-op, or post op external beam radiation therapy. The feasibility, toxicity and efficacy of PBI ar... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/17/2019
Locations: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Breast Cancer
Register for Updates
Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
NCT00495170
Completed
The goal of this clinical research study is to learn if proton radiotherapy given with standard chemotherapy (such as paclitaxel and carboplatin) can help to control locally advanced NSCLC. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
All
Trial Updated:
01/17/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00547443
Withdrawn
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving sorafenib together with high-dose chemotherapy and external-beam radiation therapy may kill m... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/08/2019
Locations: Arlington Cancer Center - Arlington, Arlington, Texas +1 locations
Conditions: Lung Cancer
Register for Updates
A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
NCT02187744
Completed
The current study will compare PK, efficacy, safety, and immunogenicity of PF-05280014 (Trastuzumab-Pfizer) in combination with Taxotere® and Carboplatin (Paraplatin) versus Herceptin® (Trastuzumab-EU) approved in the EU in combination with Taxotere® and Carboplatin (Paraplatin) in patients with operable HER2 positive, breast cancer in the neoadjuvant setting. The hypothesis to be tested in this study is the percentage of patients with steady state Cycle 5 Ctrough (Cycle 6 pre-dose) \>20 µg/mL o... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/19/2018
Locations: Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California +51 locations
Conditions: Early Breast Cancer
Register for Updates
Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer
NCT03234842
Withdrawn
This study will evaluate if proton beam therapy as part of chemoradiation results in a decrease in diffusion lung capacity of carbon monoxide (DLCO) compared to photon radiation therapy for esophageal carcinoma. A secondary objective is to determine effects on cardiac function, quality of life, and compare acute and late toxicities.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2018
Locations: University of Florida Proton Therapy Institute, Jacksonville, Florida
Conditions: Esophageal Cancer
Register for Updates